3646 results for «689»
3646 results
Coronary interventions: first-in-man and novel devices
20 May 2026 – From EuroPCR 2026
Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...
Complex left main patients and PCI
20 May 2026 – From EuroPCR 2026
This session addressed the complexities of left main PCI, focusing on managing hemodynamic uncertainty in high-risk interventions, advanced techniques such as ultra-low contrast rota-tripsy PCI, precise stent positioning, and pragmatic approaches to CHIP cases, emphasizing contrast-sparing strategies and best practice balancing.
TAVI for aortic regurgitation
20 May 2026 – From EuroPCR 2026
This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.
Imaging and physiology integration to guided PCI
20 May 2026 – From EuroPCR 2026
Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.
Performing BASILICA: a step-by-step guide to prevent coronary obstruction during TAVI
05 Aug 2025
Author
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
